Why the study?
Do saliva-based nano-biochip tests provide a feasible and rapid screening method for acute myocardial infarction in prehospital settings?
Do saliva-based nano-biochip tests provide a feasible and rapid screening method for acute myocardial infarction in prehospital settings?
Saliva-based nano-biochip tests may serve as a feasible, rapid point-of-care screening tool for acute myocardial infarction in prehospital settings, complementary to ECG.
Complementary to ECG, saliva-based tests within lab-on-a-chip systems may provide a convenient and rapid screening method for cardiac events in prehospital stages for AMI patients.
No takes yet. Share an insight, caveat, or question.
Floriano et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: